Published in Cancer Weekly, July 24th, 2007
Progen has used key outcomes from its Phase 2 trial and combined input from its Phase 3 Clinical Advisory Board, specialist advisers, and the FDA to design a Phase 3 trial with optimized probability of success. One key design feature of the Phase 3 trial will be the use of disease-free survival (DFS) as a primary endpoint, which reduces the overall cost and timelines...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly